Tofajak Tofacitinib 5mg

Tofacitinib 5mg price in India, uses, and side effects

Tofacitinib India Price

Price: INR 1100/Bottle| MRP INR 1200

Packaging Size 60 Tablets
Strength 5mg
Composition Tofacitinib
Form Tablet
Brand Tofajak
Manufacturer Cipla Ltd

FAQ - Tofacitinib

Tofacitinib, sold under the brand name Xeljanz among others like Tofajak, Jakura, Jaknat, T Jaki, etc, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Tofacitinib 5mg price in India INR 1500

Tofacitinib citrate is made by combining equimolar amounts of tofacitinib and citric acid. This medication is used to treat moderately to severely active rheumatoid arthritis. It functions as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor as well as an antirheumatic agent. Tofacitinib is present.

Tofacitinib citrate is a Janus kinase 1/3 inhibitor that was previously used to treat rheumatoid arthritis, but it is now being used to treat alopecia areata. In this study, researchers searched the Cleveland Clinic’s medical records for patients with confirmed AA who were treated with oral tofacitinib using a standardized, systematic treatment regimen.

Tofacitinib inhibits intracellular signalling from the receptor to the cellular nucleus as well as inflammation via a novel pathway (inhibition of Janus kinases) not available to biological medicines.

Side effects tofacitinib

  • Black, tarry stools.
  • bladder pain.
  • bloody or cloudy urine.
  • body aches or pain.
  • chest pain or tightness.
  • difficult, burning, or painful urination.
  • difficulty breathing.
  • ear congestion.

Tofacitinib, sold under the brand name Xeljanz among others like Tofajak, Jakura, Jaknat, T Jaki, etc,

Vitiligo is an autoimmune skin disease that causes areas of depigmentation on the skin.

Vitiligo is an autoimmune skin disease that causes areas of depigmentation on the skin. According to recent research, Janus kinase (JAK) inhibitors may be an effective treatment. We present our experience with an adolescent patient with a long history of generalised and refractory vitiligo, for whom 9 months of treatment with topical tofacitinib, a JAK inhibitor, combined with phototherapy resulted in near complete repigmentation.